We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oral Anti-HCV Drug Development

The discovery and development of potent anti-hepatitis C virus (HCV) therapies has been a hotly contested field for global pharmaceutical companies over the last few decades. Some natural products, such as sangliferin A (SfA), have demonstrated potent anti-HCV activity through the inhibition of a clinically validated target, cyclophilin A (CypA).

Unfortunately, the chemical complexity of SfA and poor oral bioavailability have derailed all early drug development attempts.

This case study:

  • Follows the success of Eurofins Discovery and their DiscoveryOne™ integrated drug discovery services team as they collaborate with a global pharma company.
  • Demonstrates how Eurofins helped the company overcome the challenges faced in this area - with pleasing results.